Background: The posterior wall of the left atrium (LA) is a well-known substrate for atrial fibrillation (AF) maintenance. Isolation of the posterior wall between the pulmonary veins (box lesion) may improve ablation success. Box lesion surface area size varies depending on the individual anatomy. This retrospective study evaluates the influence of box lesion surface area as a ratio of total LA surface area (box surface ratio) on arrhythmia recurrence.
INTRODUCTION
Wide circumferential pulmonary vein isolation (PVI) is the first step in atrial fibrillation (AF) ablation as the pulmonary veins (PVs) and their antrum harbor the majority of triggers and are an important substrate for the maintenance of AF. 1 However, PVI alone in patients catheter ablation of the posterior wall, in addition to PVI, improves ablation outcome. 11, 12 Similarly, a surgical approach aiming to isolate the posterior wall resulted in 76% free of AF recurrences in patients with long-standing persistent AF. 13 The insertion of the PVs in the LA can be highly variable between patients. A larger distance between the insertion of the superior PVs and inferior PVs increases the box lesion surface area. As the potentially arrhythmogenic posterior LA is not only confined to the area between the PVs but also it may extend caudally toward the coronary sinus, 9,10,14 a variable part of the posterior LA will not be included in the box lesion, depending on the insertion of the inferior veins. In addition, with progressive left atrial dilation, the box lesion surface area as a ratio of total left atrial surface area may decrease further. We, therefore, hypothesized that differences in box lesion surface area normalized to total left atrial surface area may be an important factor influencing ablation outcome.
METHODS

Inclusion
Consecutive patients with symptomatic drug-refractory persistent AF who underwent PVI and isolation of the posterior LA between the PVs 
Ablation procedure
Prior to the procedure, patients underwent a 320-slice Computer Tomography (Aquilion ONE, Toshiba Medical Systems, Otawara, Japan) and image segmentation to visualize the anatomy of the LA and PVs and to guide the ablation. 15 The computed tomography (CT) scan was performed in a phase window between 65%-85% of R-R interval in patients with a heart rate ≥60 beats per minute and 75% of R-R interval in patients with a HR below 60 beats per minute. 16 Antiarrhythmic drugs (AADs) were discontinued for five half-lives before ablation, with the exception of amiodarone which was continued until 1 month after ablation. Catheter mapping and ablation were performed under uninterrupted anticoagulation with a double transseptal approach using a 3D electroanatomical mapping system In addition, exit block from the box lesion was demonstrated by pacing with high output (10 mA/2 ms) at the posterior LA. PVI and box lesion isolation were reconfirmed ≥30 min after the last RF application.
Follow-up
Follow-up at the outpatient clinic was performed in all patients at 3, 
Calculation of left atrial and box lesion surface areas
The total LA surface area of all patients was measured on the segmented CT data after importing the original CT data into the CARTO system using the CARTO Merge software. The box lesion surface area, bordered by the posterior circumferential ablation lines adjacent to the PV ostia, the roofline, and the posterior line was measured on the electroanatomical (EA) maps using dedicated software of CARTO and Ensite Velocity systems (Figure 1 ). In addition, the ratio of the box lesion surface area to the total LA surface area (box surface ratio) was calculated. The distances between the contralateral PVs (box lesion width), between the roof and posterior line (box lesion height), and the distance between the middle of the posterior line to the mitral annulus was measured. Both in patients with and without atypical/mitral isthmus-dependent flutter at follow-up, the distance between the posterior line and the mitral annulus was measured. For outcome comparison, the study subjects were divided into two groups according to the box surface ratio (above and below the median).
Statistical analysis
Clinical, echocardiographic, and ablation data were prospectively collected in the departmental Cardiology Information System (EPDVision, Leiden University Medical Centre, Leiden, The Netherlands) Cox proportional regression analysis was performed to detect any independent significant predictors of AF/AT recurrence reported as hazard ratio (HR) with 95% confidence interval (CI). Previously reported predictors of AF recurrence 17 after catheter ablation were tested in the univariate model. Variables with a P < 0.1 in the univariate analyses were included in the multivariate analyses using the "enter" method. P < 0.05 was considered as a significant value. All analyses were performed with the SPSS version 23 statistics software package (IBM Corp., Armonk, NY, USA).
RESULTS
Study group
During the study period, 76 patients underwent box lesion isolation, in addition to PVI. From this group, six patients were excluded (EA maps were of insufficient quality to delineate the box lesion surface area [n = 4], EA maps were not retrievable [n = 1], multislice CT scan was not performed prior to ablation [n = 1]). The remaining 70 patients (63 ± 11 years, 53 men) comprised the study population.
Baseline characteristics
Persistent AF was diagnosed in 39 (56%) patients and long-standing persistent AF in 31 (44%) patients. The median duration of AF from the first diagnosis to the index ablation procedure was 70 (IQR = 40-114) months. The LA volume index was 50 ± 22 mL/m 2 in the recurrence group and 41 ± 13 mL/m 2 in the nonrecurrence group (P = 0.050).
Thirty-one patients (56%) had undergone prior PVI. This was not significantly different between the recurrence and the nonrecurrence group. In the entire population, the median LA surface area was 196 (IQR = 172-233) cm 2 , the box lesion surface area was 20 (IQR = 18-24) cm 2 , and the median box surface ratio was 0.10 (IQR = 0.09-0.14). Eighty-four percent of the population was on AAD before the ablation. Fifty-one patients (73%) were using beta-receptor blocking drugs (sotalol: n = 27, 38%), 11 (16%) patients were using flecainide, 19 patients (27%) were using amiodarone, and two patients (3%) were using disopyramide. Four patients (6%) were on rate control with digoxin. Baseline characteristics are provided in Table 1 . Table 2 provides the procedural details of the index ablation including additional ablation lesions beyond PV and box isolation. The box lesion was successfully isolated in 67 patients (96%), while isolation could not be achieved in three patients despite extensive ablation.
Procedural characteristics and complications
Thirty-five patients (50% of the cases in which the index procedure was a reablation) underwent a redo PVI. Additional ablation (focal AT ablation, continuous fractionated atrial electrogram ablation, superior vena cava ablation, and mitral isthmus ablation) during the index procedure was performed in 10 (14%) patients. This was equally distributed between the groups and was not significantly different.
One patient (1%) had a complication related to the vascular access Values are reported as the mean ± standard deviation, median (interquartile range), or n (%). AAD = antiarrhythmic drug; AF = atrial fibrillation; AT = atrial tachycardia; eGFR = estimated glomerular filtration rate; LA = left atrium; LV = left ventricle; NOAC = novel oral anticoagulant; OSAS = obstructive sleep apnea; PVI = pulmonary vein isolation. Additional ablation, n (%) 10 (14) 6 (14) 4 (14) 1.000
Follow-up
TA B L E 2
Values are reported as the mean ± standard deviation, median (interquartile range), or n (%). AF = atrial fibrillation; AT = atrial tachycardia; CFAE = continuous fractionated atrial electrogram; LA = left atrium; SVC = superior vena cava.
symptoms and the tachycardia improved from persistent to paroxysmal. AF-free survival off ADD was 40%. AF-free survival on/off AAD was higher (59%). There was no significant difference in recurrence between patients undergoing ablation with and without contact force sensing (62% vs 55% P = 0.589). Before the ablation, AADs usage (84% in the total group) was not significantly different between the groups.
In the no-recurrence group after the blanking period of 3 months, 38 patients (90%) stopped all AADs and four patients (10%) continued with sotalol in a lower dosage at the discretion of the treating physician as beta-blockade therapy was indicated for concomitant coronary artery disease.
Predictors of AF/AT recurrence
In univariate analysis, a larger LA volume, a history of prior mitral valve surgery, and a smaller box surface ratio were associated with AF/AT recurrence (P ≤ 0.1). Male gender; type and duration of AF; body mass index; CHA 2 DS 2 -VASc score; and previous PVI box lesion width, height, and surface area were not associated with AF recurrence ( 
Repeat procedures
In 15 patients, a reablation was performed after the index box lesion isolation. In all patients, isolation of the PVs and of the box lesion was checked and/or an additional ablation was performed. Two patients underwent a His-ablation after a permanent pacemaker insertion. In the remaining 13, re-PV isolation (n = 9), reisolation of box lesion (n = 9), superior vena cava isolation (n = 1), mitral isthmus ablation (n = 4), anterior box lesion isolation (n = 1), and other LA AT ablation (n = 4) were performed. Out of 13 patients, follow-up data were available in 10 patients (two lost to follow-up). In one patient, the procedure was aborted because of a cardiac tamponade and AF was accepted. months. In summary, AF-free survival after the index procedure was 40% and after the repeated procedures was 51% off AADs. AF-free survival on/off AAD in the entire group after the repeated procedures was 64%.
DISCUSSION
Main findings
The major finding of this study is that a larger box lesion surface area as a ratio of total left atrial surface area is protective for AF/AT recurrence after ablation for persistent AF. To the best of our knowledge, this is the first study that investigated box lesion surface area ratio in relation to ablation outcome.
Benefit of substrate modification beyond PVI
The necessity of extending the ablation beyond PVI by performing substrate modification in patients with persistent AF is currently controversial due to the STAR-AF II trial, in which no benefit of additional ablation beyond PVI was demonstrated 18 wall. In line with these results, we recently published a 76% success rate with a standalone surgical box lesion in persistent AF. 13 A metaanalysis comparing catheter ablation of PVI versus PVI with box lesion also showed a benefit of adding a box lesion to PVI in patients with persistent AF. 11 In the current study, 1-year success was 40% after a single procedure off AADs and 64% after repeated procedures on/off AAD. Bai et al recently reported an AAD-free survival of 65%, 50%, and 40% after 1, 2, and 3 years of follow-up, respectively, in persistent AF after catheter ablation of the posterior wall. 23 Lim et al reported a 2-year AT/AF drug-free survival of 53% in patients with persistent AF. 24 The difference in outcome between surgical and catheter-based isolation of a box lesion can be explained by the higher durability of surgical ablation compared to catheter-based ablation lesions. 25 It is unknown if the area of the box lesion in patients undergoing a surgical box lesion is larger than patient undergoing catheter ablation.
As ablation lines have to be connected to anatomical barriers to prevent scar-related reentry, the roof line of a box lesion is connected to the superior ostia of the superior veins and the posterior line of a box lesion is connected to the inferior ostia of the inferior PVs. However, the anatomical posterior LA is not limited to the area between the veins but extends more caudally toward the coronary sinus. 14, 26 In the current study, patients with a small box surface ratio had a decreased arrhythmia-free survival compared to patients with a large box surface ratio, while box lesion width, height, and surface area; total LA surface area; and LA volume were not predictive. A possible explanation is the extent of isolation of the posterior wall, which shares the same embryologic origin with that of the PVs, containing the substrate for AF maintenance. Although the ratio of the isolated box lesion surface area and the total LA surface was calculated, box lesion surface area as a ratio of total left atrial posterior wall surface area could be superior to sustain our hypothesis. However, as the borders of the posterior wall of the LA are not well-defined in the literature, we did not adopt this parameter.
A second explanation of our findings may be that an increase in left atrial size outside the area between the PVs will also decrease the box surface ratio. It may be hypothesized that enlargement of the LA will be more distinct outside the box lesion while the box lesion itself may be more resistant to dilation, as this area is bounded by the PVs. Therefore, the combination of anatomical variation and left atrial dilation outside the box lesion may explain why box surface ratio was predictive of outcome, while box lesion length, width, and surface area were not.
It remains to be proven that the positive influence of a large box lesion is dependent on the substrate modification of the LA posterior wall and not on the extensive atrial debulking per se. Preprocedural visualization of a small posterior LA box as a ratio of left atrial surface could be an important factor in predicting failure in patients in whom a box lesion is considered.
Clinical implications
The box lesion surface area and total left atrial surface area can be measured during the procedure irrespective from prior imaging. In concordance with the fact that the AF substrate in the LA posterior wall is not confined to the area between the PVs, it may be hypothesized that ablation of a relatively larger box lesion is beneficial. This may support a decision to increase the size of the box lesion; for example, extending it inferiorly below the level of the PVs toward the coronary sinus, especially in patients with a relatively small anatomical box lesion. However, this hypothesis needs to be proven in further studies. Concordantly, Di Biase et al described PVI together with an extensive box lesion extended down to the coronary sinus and to the left-sided atrial septum in patients with persistent AF and heart failure. 27 Two-year follow-up demonstrated 70% freedom from AF/AT off AADs. This is a very respectable outcome considering that heart failure patients with persistent AF are at high risk for recurrence of AF. 28 It may be reasoned that the extensive box lesion performed in this study explains the high success rate in these patients with heart failure and persistent AF.
Limitations
The present study is a single-center, retrospective study in a small group of patients. Due to the small group of patients, this study may have been underpowered to detect other parameters influencing arrhythmia recurrence. Therefore, this study should be considered as "hypothesis generating." Several prior studies already have presented data on the value of isolating the posterior wall; however, the aim of this study was not to evaluate the value of posterior wall isolation, but the influence of the size of the ablated anatomical box lesion surface area as a ratio of total left atrial surface area on the outcome of this procedure. Our study did not show that extending the inferior line between the inferior poles of the inferior PVs improved the outcome. Further larger and randomized studies need to confirm that a relatively larger box lesion or extension of the box lesion inferior from the inferior ostia of the PVs protects against arrhythmia recurrence. In the study population, 56% had undergone a prior PVI, which can have influenced the results. However, this was not significantly different between the groups. During the index procedure in 10 patients (14%), an additional ablation was performed; this was, however, not significantly different between the groups. Moreover, when these 10 patients were excluded from the analysis, the study results remained unchanged. Only repeated 24-h Holter monitoring was used during follow-up. Therefore, asymptomatic AF episodes may have been missed. The recurrence group had more often LA enlargement compared to the nonrecurrence group. However, this number was not significant in multivariate analysis. During the procedure, durable isolation of the PVs and box lesion was not enhanced using maneuvers, such as the pace/ablate method 29 other LA regions could be helpful. Despite the limitations, we believe that this study is an important scientific contribution with potentially valuable suggestions for further research. Box lesion surface ratio is a new parameter to predict outcome in persistent AF ablation and we think that our hypothesis-generating study will trigger new research on extending the box lesion in patients with a small box lesion surface ratio to improve the outcomes.
